NSE: GRANULES | BSE: 532482

Mid-range Performer

Download real time

607.35 -3.60 (-0.59%)

New 52W High in past week

1.6M NSE+BSE Volume

NSE 08 Jan, 2026 3:31 PM (IST)

14,738.5

Market Cap

High in industry

Beta 1Year

Very High Volatility

US FDA Approval

Granules India's arm receives US FDA approval for an ADHD drug, with a market size of $41 million See details

Granules India Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GRANULES, BSE:532482 Granules India Ltd.

Search Inside the pdf :

Granules India Ltd.

17 Nov 2025

607.35

-0.59%

Granules India

Buy: Granules India Ltd.

Target

ICICI Direct

The YoY numbers for the quarter are not comparable due to low base of FY25. Post the Gagillapur USFDA warning letter, the company has focused on developing other facilities and also focused on incremental flings across markets. Besides CNS and ADHD, it is also focusing on Oncology as a segment with dedicated API and formulations block at Vizag. The management expects full revival of Gagillapur facility post clearance from the USFDA (Management meeting with USFDA scheduled in Jan 26) by filing new products. On the margins front, the numbers continued to...

Granules has gained 23.14% in the last 6 Months

Granules India Ltd.

17 Nov 2025

607.35

-0.59%

A quarter marked by Regulatory Progress, Capacity Unlocks and Peptide/CDMO Scale-Up

Accumulate: Granules India Ltd.

Recommendation Target

Deven Choksey

Granules India appears to be entering a phase of structural recovery, supported by steady progress on regulatory milestones (notably the remediation of Gagillapur) and a 40% incremental formulation capacity expansion at its Genome Valley site, which should meaningfully reduce supply constraints.

Granules India Ltd. has an average target of 632.00 from 4 brokers.

Granules India Ltd.

13 Nov 2025

607.35

-0.59%

FD remains on a robust footing

Buy: Granules India Ltd.

Target

Motilal Oswal

Granules India (GRAN) delivered better-than-expected operational performance (9.5%/8.3% beat on revenue/EBITDA). However, earnings were in line with estimates due to higher depreciation and tax rate for the quarter.

Granules India Ltd. is trading above all available SMAs

Granules India Ltd.

18 Sep 2025

607.35

-0.59%

GRANULES INDIA

Accumulate: Granules India Ltd.

Target

Geojit BNP Paribas

We remain positive on Granules' long-term growth and profitability, supported by new product launches across geographies, a focus on backward integration, and rising market share. Entry into the CDMO segment via the Senn acquisition, along with higher-margin oncology filings, is expected to strengthen financials. Moreover, resolution of regulatory issues at the Gagilapur facility could act as a key re-rating catalyst. Hence, we maintain an Accumulate rating on the...

Number of FII/FPI investors decreased from 199 to 189 in Sep 2025 qtr

Granules India Ltd.

22 Aug 2025

607.35

-0.59%

Modest Q1FY26 growth; facility ramp-up to drive recovery

Buy: Granules India Ltd.

Deven Choksey

We have revised our FY26E/FY27E EPS estimates by -0.6%/-4.6% primarily to reflect a more gradual post-remediation ramp-up at Gagillapur, and a measured margin recovery amid persistent integration and operating costs.

Mutual Funds have decreased holdings from 12.24% to 6.54% in Sep 2025 qtr

Granules India Ltd.

06 Jun 2025

607.35

-0.59%

GRANULES INDIA

Accumulate: Granules India Ltd.

Target

Geojit BNP Paribas

Validation activities have begun in Phase 2, Genome Valley, in this quarter. Also, the company continues to invest in research and development efforts aimed at building a pipeline of high-value molecules, with a focus on backward integration, especially in the oncology and CNS segment. The company has filed its first oncology molecule in this quarter....

Number of MF schemes decreased from 28 to 17 in Sep 2025 qtr

Granules India Ltd.

28 May 2025

607.35

-0.59%

Broadly in-line quarter; margin resilience led by FDF

Buy: Granules India Ltd.

Target

Motilal Oswal

Granules India (GRAN) delivered a slightly better-than-expected revenue in 4QFY25. However, it reported largely in-line EBITDA/PAT for the quarter.

Number of MF schemes decreased from 28 to 17 in Sep 2025 qtr

Granules India Ltd.

17 Feb 2025

607.35

-0.59%

GRANULES INDIA

Accumulate: Granules India Ltd.

Target

Geojit BNP Paribas

Mutual Funds have decreased holdings from 12.24% to 6.54% in Sep 2025 qtr

Granules India Ltd.

25 Jan 2025

607.35

-0.59%

Finished dosages remain the key earnings driver

Buy: Granules India Ltd.

Target

Motilal Oswal

Granules India (GRAN) delivered better-than-expected revenue, while EBITDA/PAT stood in line for the quarter. The traction in finished dosage (FDF) remained robust for six quarters now.